Dear Luis,

Please check out the following paper:

Dear Luis,

for an overview relating to both Type 1 and Type 2 diabetes, check out the following article: Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore

G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L; SEARCH

for Diabetes in Youth Study. Incidence Trends of Type 1 and Type 2 Diabetes among

Youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-1429. doi:

10.1056/NEJMoa1610187. PubMed PMID: 28402773.

When it comes to therapies, there are recent studies such as:

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE,

Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB;

DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2

Diabetes. N Engl J Med. 2017 Jun 12. doi: 10.1056/NEJMoa1615692. [Epub ahead of

print] PubMed PMID: 28605603.

or

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law

G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and

Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Jun 12.

doi: 10.1056/NEJMoa1611925. [Epub ahead of print] PubMed PMID: 28605608.

or

Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak

I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA,

Sattar N, Colhoun HM; REMOVAL Study Group. Cardiovascular and metabolic effects

of metformin in patients with type 1 diabetes (REMOVAL): a double-blind,

randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Jun 9.

pii: S2213-8587(17)30194-8. doi: 10.1016/S2213-8587(17)30194-8. [Epub ahead of

print] PubMed PMID: 28615149.

Sincerely,

Rainer